Philips Respironics recalls certain V60, V60 Plus ventilators because expired adhesive could cause some to stop working; Adamis Pharmaceuticals recalls certain lots of epinephrine injection because needle may clog, prevent drug from dispensing

Sample article from our Health Care Sector

March 25, 2022 (press release) –

Philips Respironics has recalled certain V60 and V60 Plus ventilators because some of them could stop working due to an expired adhesive, the Food and Drug Administration announced this week. FDA has identified this as a Class 1 recall, the most serious type because it may cause serious injury or death. No injuries or adverse health consequences have been reported. 

In other news, Adamis Pharmaceuticals Corp. has recalled certain lots of epinephrine injection, an emergency treatment for allergic reactions, because the needle may clog and prevent the drug from dispensing. Health care providers may report associated adverse reactions or quality problems to the FDA's MedWatch program.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.